It is generally accepted that FGFR3 and TP53 alterations characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma and are hallmarks of specific BC types: FGFR3 mutations are observed in 59% and TP53 overexpression in 25% of primary BC. This evidence concerns the gene TP53 and breast cancer.